ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline

ALX ONCOLOGY HOLDINGS INC

2025-Q1 EPS reported -$0.58

Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.
Received IND clearance from FDA for ALX2004, a novel EGFR-targeted ADC; Phase 1 initiation expected mid-2025 with initial safety data in 1H 2026.
Will not pursue U.S. registrational path for evorpacept in gastric cancer after FDA feedback that accelerated approval not feasible due to ENHERTU®.
Discontinued evorpacept in combination with PADCEV® in urothelial cancer due to lack of improved efficacy in ASPEN-07 trial.
Expect to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies mid-2025, with data milestones in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.